Analytical methods for dissolution testing of nanosized drugs

Journal of Pharmacy and Pharmacology

Volumn 64, Issue 7, 2012, Pages 931-943

  Jünemann, Daniel ^a   Dressman, Jennifer ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

biorelevant dissolution; dissolution analytics; dissolution rate enhancement; in vitro in vivo correlation; nanonization

Indexed keywords

APREPITANT; FENOFIBRATE; MEGESTROL ACETATE; NANOCRYSTAL; NANOPARTICLE; PALIPERIDONE; RAPAMYCIN;

BIOEQUIVALENCE; CONTROLLED DRUG RELEASE; DIFFUSION; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG SOLUBILITY; FIBER OPTICS; FIELD FLOW FRACTIONATION; FILTER; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; ION SELECTIVE ELECTRODE; MICRODIALYSIS; NANOPHARMACEUTICS; PARTICLE SIZE; REVIEW; SCHIZOPHRENIA; SIMULATION; SURFACE PROPERTY; TURBIDITY; ULTRASONIC RESONATOR TECHNOLOGY; ULTRASOUND;

CHEMISTRY, PHARMACEUTICAL; DIFFUSION; DOSAGE FORMS; HUMANS; NANOPARTICLES; PARTICLE SIZE; PHARMACEUTICAL PREPARATIONS; SOFTWARE; SOLUBILITY;

EID: 84862188422     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2012.01520.x     Document Type: Review

References (64)

1. Cohen JL, et al,. The development of USP dissolution and drug release standards. Pharm Res 1990; 7: 983-987. (Pubitemid 20366722)
2. Lindenbaum J, et al,. Variation in biologic availability of digoxin from 4 preparations. N Engl J Med 1971; 285: 1344-1347.
3. Fraser EJ, et al,. Bioavailability of digoxin. Lancet 1972; 2: 541.
4. Fraser EJ, et al,. Dissolution-rates and bioavailability of digoxin tablets. Lancet 1973; 1: 1393-1393.
5. Shaw TR,. Non-equivalence of digoxin tablets in the UK and its clinical implications. Postgrad Med J 1974; 50 (Suppl. 6): 24-29.
6. Jounela AJ, et al,. Effect of particle-size on bioavailability of digoxin. Eur J Clin Pharmacol 1975; 8: 365-370.
7. Dressman JB, Fleisher D,. Mixing-tank model for predicting dissolution rate control or oral absorption. J Pharm Sci 1986; 75: 109-116. (Pubitemid 16162530)
8. Melander A,. Influence of food on the bioavailability of drugs. Clin Pharmacokinet 1978; 3: 337-351. (Pubitemid 9013897)
9. Dressman JB, et al,. Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms. Pharm Res 1998; 15: 11-22. (Pubitemid 28080861)
10. Noyes A, Whitney W,. The rate of solution of solid substances in their own solutions. J Am Chem Soc 1897; 19: 930-934.
11. Guichard JP, et al,. A new formulation of fenofibrate: suprabioavailable tablets. Curr Med Res Opin 2000; 16: 134-138. (Pubitemid 30426776)
12. Liversidge GG, Cundy KC,. Particle-size reduction for improvement of oral bioavailability of hydrophobic drugs. 1. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs. Int J Pharm 1995; 125: 91-97.
13. Merisko-Liversidge E, et al,. Nanosizing: a formulation approach for poorly-water-soluble compounds. Eur J Pharm Sci 2003; 18: 113-120. (Pubitemid 36184748)
14. Moschwitzer J, Muller RH,. Spray coated pellets as carrier system for mucoadhesive drug nanocrystals. Eur J Pharm Biopharm 2006; 62: 282-287. (Pubitemid 43356577)
15. Muller RH, et al,. Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. Adv Drug Deliv Rev 2001; 47: 3-19. (Pubitemid 32209229)
16. Muller RH, Keck CM,. Challenges and solutions for the delivery of biotech drugs-a review of drug nanocrystal technology and lipid nanoparticles. J Biotechnol 2004; 113: 151-170. (Pubitemid 39237077)
17. Rabinow BE,. Nanosuspensions in drug delivery. Nat Rev Drug Discov 2004; 3: 785-796. (Pubitemid 39242830)
18. Keck CM, Muller RH,. Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation. Eur J Pharm Biopharm 2006; 62: 3-16. (Pubitemid 41736019)
19. Kesisoglou F, et al,. Nanosizing-oral formulation development and biopharmaceutical evaluation. Adv Drug Deliv Rev 2007; 59: 631-644. (Pubitemid 47285408)
20. Sauron R, et al,. Absence of a food effect with a 145 mg nanoparticle fenofibrate tablet formulation. Int J Clin Pharmacol Ther 2006; 44: 64-70. (Pubitemid 43230588)
21. Hixson AW, Baum SJ,. Agitation-mass transfer coefficients in liquid-solid agitation systems. Ind Eng Chem 1941; 33: 478-485.
22. Sheng JJ, et al,. Particle diffusional layer thickness in a USP dissolution apparatus II: a combined function of particle size and paddle speed. J Pharm Sci 2008; 97: 4815-4829.
23. Higuchi WI, Hiestand EN,. Dissolution rates of finely divided drug powders. 1. Effect of a distribution of particle sizes in a diffusion-controlled process. J Pharm Sci 1963; 52: 67-71.
24. Higuchi WI, et al,. Dissolution rates of finely divided drug powders. 2. Micronized methylprednisolone. J Pharm Sci 1963; 52: 162-164.
25. Niebergall PJ, et al,. Dissolution rate studies. 2. Dissolution of particles under conditions of rapid agitation. J Pharm Sci 1963; 52: 236-241.
26. Hintz RJ, Johnson KC,. The effect of particle-size distribution on dissolution rate and oral absorption. Int J Pharm 1989; 51: 9-17. (Pubitemid 19087827)
27. Willmann S, et al,. Mechanism-based prediction of particle size-dependent dissolution and absorption: cilostazol pharmacokinetics in dogs. Eur J Pharm Biopharm 2010; 76: 83-94.
28. Delie F,. Evaluation of nano- and microparticle uptake by the gastrointestinal tract. Adv Drug Deliv Rev 1998; 34: 221-233. (Pubitemid 28535113)
29. Doyle-McCullough M, et al,. Factors influencing intestinal microparticle uptake in vivo. Int J Pharm 2007; 335: 79-89.
30. Florence AT,. The oral absorption of micro- and nanoparticulates: neither exceptional nor unusual. Pharm Res 1997; 14: 259-266. (Pubitemid 27160935)
31. Miao ZM, et al,. Study on drug release behaviors of poly-alpha,beta-[n- (2-hydroxyethyl)-L-aspartamide]-g-poly(epsilon-caprolac tone) nano- and microparticles. Biomacromolecules 2006; 7: 2020-2026.
32. Chidambaram N, Burgess DJ,. A novel in vitro release method for submicron sized dispersed systems. AAPS PharmSci 1999; 1: E11.
33. Macheras P, et al,. Drug dissolution studies in milk using the automated flow-injection serial dynamic dialysis technique. Int J Pharm 1986; 33: 125-136.
34. Johansson J, et al,. Multiple fiber-optic dual-beam UV/Vis system with application to dissolution testing. J Pharm Biomed Anal 2002; 29: 469-476. (Pubitemid 34607807)
35. Roinestad KC, et al,. Detection systems and methods for predicting the dissolution curve of a drug from a pharmaceutical dosage form. P. Inc., Editor. 2001, Euro-Celtique, S.A. (Luxembourg, LU) United States of America.
36. Wunderlich M, et al,. Practical considerations when using fiber optics for dissolution testing. Dissolution Tech 2003; 10: 17-19.
37. Josefson M, et al,. Optical fiber spectrometry in turbid solutions by multivariate calibration applied to tablet dissolution testing. Anal Chem 1988; 60: 2666-2671. (Pubitemid 19013613)
38. Galia E, et al,. Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs. Pharm Res 1998; 15: 698-705. (Pubitemid 28275645)
39. Liu F, et al,. Technical evaluation of a fiber-optic probe dissolution system. Dissolut Technol 2008; 15: 10-20.
40. Jantratid E, et al,. Dissolution media simulating conditions in the proximal human gastrointestinal tract: an update. Pharm Res 2008; 25: 1663-1676.
41. Crisp MT, et al,. Turbidimetric measurement and prediction of dissolution rates of poorly soluble drug nanocrystals. J Control Release 2007; 117: 351-359. (Pubitemid 46216578)
42. Klein T, Hürzeler C,. Charakterisierung von Biopolymeren, Proteinen, Partikeln und Kolloiden mit Feldflussfraktionierung. GIT Laborfachzeitschrift 1999; 11: 1224-1228.
43. Hürzeler C, Böswirth B,. Größencharakterisierung von Biopolymeren und Biopartikeln mit Feldflussfraktionierung und on-line dynamischer Lichtstreuung. Artikel GIT Laborfachzeitschrift 2000; 3: 271-274.
44. Klein T,. Postnova Analytics-Company Presentation. Frankfurt: Postnova Analytics, 2008.
45. Goodman JC,. Clinical microdialysis in neuro-oncology: principles and applications. Chin J Cancer 2011; 30: 173-181.
46. Shah KP, et al,. Automated analytical systems for drug development studies. II-a system for dissolution testing. J Pharm Biomed Anal 1994; 12: 1519-1527.
47. Shah KP, et al,. Automated analytical systems for drug development studies. 3. Multivessel dissolution testing system based on microdialysis sampling. J Pharm Biomed Anal 1995; 13: 1235-1241.
48. Shah KP, et al,. Automated analytical systems for drug development studies. I-a system for the determination of drug stability. J Pharm Biomed Anal 1994; 12: 993-1001. (Pubitemid 24263490)
49. Dash AK, et al,. Development of an in vitro dissolution method using microdialysis sampling technique for implantable drug delivery systems. J Pharm Sci 1999; 88: 1036-1040. (Pubitemid 29480596)
50. TF Instruments GmbH. Resoscan. 2012; Available from: (accessed 17 April 2012).
51. Valsami GN, et al,. Construction of a naproxen ion-selective electrode and its application to pharmaceutical analysis. Analyst 1989; 114: 387-391. (Pubitemid 19085338)
52. Mitsana-Papazoglou A, et al,. Dissolution studies of drug formulations using ion-selective electrodes as sensors in an air-segmented continuous flow analyzer. J Pharm Sci 1987; 76: 724-730. (Pubitemid 18026983)
53. Solich P, et al,. Construction of a diflunisal ion sensor and its use in automated flow-injection methods for assay, content uniformity, and dissolution studies of formulations. J Pharm Sci 1995; 84: 889-894.
54. Bohets H, et al,. Development of in situ ion selective sensors for dissolution. Anal Chim Acta 2007; 581: 181-191. (Pubitemid 44779501)
55. Peeters K, et al,. In situ dissolution testing using potentiometric sensors. Eur J Pharm Sci 2008; 34: 243-249.
56. Juenemann D, et al,. Online monitoring of dissolution tests using dedicated potentiometric sensors in biorelevant media. Eur J Pharm Biopharm 2011; 78: 158-165.
57. Shono Y,. Forecasting in vivo oral absorption and food effect of micronized and nanosized aprepitant formulations in humans. Eur J Pharm Biopharm 2010; 76: 95-104.
58. Lindenberg M, et al,. Comparison of the adsorption of several drugs to typical filter materials. Dissolut Technol 2005; 12: 22-25.
59. Juenemann D, et al,. Biorelevant in vitro dissolution testing of products containing micronized or nanosized fenofibrate with a view to predicting plasma profiles. Eur J Pharm Biopharm 2011; 77: 257-264.
60. Rinaki E, et al,. The mean dissolution time depends on the dose/solubility ratio. Pharm Res 2003; 20: 406-408. (Pubitemid 36288369)
61. Kipp JE,. The role of solid nanoparticle technology in the parenteral delivery of poorly water-soluble drugs. Int J Pharm 2004; 284: 109-122. (Pubitemid 39349144)
62. Nicolaides E, et al,. Biorelevant dissolution testing to predict the plasma profile of lipophilic drugs after oral administration. Pharm Res 2001; 18: 380-388. (Pubitemid 32595828)
63. Shono Y, et al,. Prediction of food effects on the absorption of celecoxib based on biorelevant dissolution testing coupled with physiologically based pharmacokinetic modeling. Eur J Pharm Biopharm 2009; 73: 107-114.
64. Nicolaides E,. Contribution to the Prediction of Absorption of Lipophilic Drugs Based on in Vitro Dissolution Data. Athens: National and Kapodistrian University of Athens, 2000.